← SynDRA
BMS-911543
SynDRA canonical compound SYN0038246 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | JAK1 | JAK3 | TYK2 |
|---|
| Mechanism of action | JAK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- JAK1 INHIBITOR
- JAK3 INHIBITOR
- TYK2 INHIBITOR
- JAK inhibitor
- JAK2 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP1A2
- CYP3A4
- SYK
- NQO2
- AAK1
- OPA1
- PDGFRB
- PAK6
- PAK4
- PAK2
- PAICS
- NUAK2
- OLA1
- PEBP1
- NR1I2
- NLK
- NEK9
- NEK7
- PDXK
- PGRMC1
- PFKP
- PLK1
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PKN2
- NEK2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
- PIM1
- PHKG2
- NEK3
- NEK1
- PRKAR2A
- NDUFA13
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP3A7
- KSYK
- NSD2
- PDE4A
- PDE4B
- PDE4C
- PDE4D
Cross-references
Synonyms
- BMS911543
- ENSG00000096968
- JAK2 INHIBITOR BMS-911543
- JTK10
- THCYT3
- BMS 911543
- UNII-7N03P021J8
- 7N03P021J8
- N,N-Dicyclopropyl-4-[(1,5-Dimethyl-1h-Pyrazol-3-Yl)amino]-6-Ethyl-1-Methyl-1,6-Dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-Carboxamide
- N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide
- N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide
- JCINBYQJBYJGDM-UHFFFAOYSA-N
- RefChem:120755
- DTXCID1077894
- MFCD22200575
- GTPL7954
- orb1300463
- SCHEMBL1512419
- SCHEMBL28561658
- SCHEMBL29401424
- SCHEMBL30925302
- GLXC-90187
- HMS3747C07
- EX-A1551
- WAC02290
- BDBM50122318
- NSC766821
- NSC799366
- s7144
- BMS 911543 [WHO-DD]
- AKOS027251175
- CCG-269045
- CS-3237
- EBC-220047
- NSC-766821
- NSC-799366
- SB16625
- BMS-911543?
- NCGC00345798-01
Look up BMS-911543 in the interactive SynDRA portal →